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Summary
The study of prethymic stages of T cell development has been limited because specific markers
for mouse pro-T lymphocytes were not available. We developed a panel of rat monoclonal antibodies
(mAbs) that bind to our pro-T lymphocyte clones obtained from bone marrow of young adult
mice and the thymus of 14-d-old embryos. The mAbs, called Joro 30-8, Joro 37-5, and Joro
75, were found to bind to all pro-T clones tested but not to cell lines representing later stages
of T cell development, B lymphocyte, or myeloid lineages. We determined the frequency and
tissue distribution in normal and immunodeficient mouse strains as well as the ontogeny in liver
and thymus of cells positive for these mAbs. The results were consistent with the pattern of
reactivity observed with cell lines. We isolated Joro 30-8+, Joro 37-5+, and Joro 75+ bone
marrow cellsby cell sorter and found that: (a) phenotypically, they are Thy-1+, CD4- , CD8-,
CD3-, B-220-, IgM-, F4/80-, and PgP-1+; (b) they grew in response to the combination of
interleukin 3 (IIr3) + IIr4 or IIr3 + IIr4 + IIr6; and (c) Joro 37-5+ and Joro 75+ marrow
cells gave rise to mature T lymphocytes but not to B lymphocytes, while Joro 30-8+ marrow
cells generated both T and B lymphocytes after 8-12 wk of transfer into severe combined
immunodeficient (Scid) mice. In normal mice subjected to 600 rad of irradiation to induce a
wave of thymus recolonization, we found by flow fluorocytometry analysis that Joro+ cells
entered the thymus 2 d after irradiation, expanded during the next 4 d, and underwent further
differentiation, and from day 8 up to day 21, post-irradiation Joro+ cells were no longer de-
tectable in the thymuses. Immunohistochemical analysis of normal thymus shows the presence
of very few Joro 30-8+, Joro 37-5+, and Joro 75+ lymphoid cells in the subcapsular area and
outer cortex but not in the medulla. The kinetic analysis of tissue sections from thymuses at
various days post-irradiation suggests that Joro+ cells enter the thymus via blood vessels through
the subcapsular and outer cortex areas; subsequently, these cells seem to migrate to the inner
cortex without reaching the medulla, and give rise to Joro thymocytes. We conclude that in
bone marrow of young mice, cells expressing Joro 30-8 are very early hematopoietic precursor
cells that are either committed to the lymphocyte pathway or are even less differentiated pluripotent
cells. Commitment to T cell differentiation appears to be associated with additional expression
of Joro 37-5 and Joro 75.
D
uringmouse development, hematopoietic precursor cells
from fetal liver colonize the thymus; in postnatal life,
the thymus is seededby precursor cells from the bone marrow
(1-4). The immigrant precursors proliferate and differentiate
in this environment, giving rise to thymocytes and eventu-
ally to functional peripheral T lymphocytes. The process of
T cell differentiation within the thymus has been studied by
cell surface phenotyping and the analysis of TCR gene rear-
rangements (5-10). However, the study of prethymic stages
ofT cell development has been limitedbecause specific markers
for mouse T cell progenitors were not available. Recently,
it has been found that a small population of bone marrow
cells (0.1-0.3%) expressing Thy-1 and Sca-1 surface antigens,
and lacking surface markers expressed by T and B lympho-
cytes or myeloid cells, possessed thymus-repopulating poten-
tial (11). However, neither Thy-1 nor Sca-1 are specific markers
for T cell progenitors and/or pluripotent stem cells (12, and
our unpublished results) .
Over the last 5 yr, we have established several T cell pro-
genitor clones from the bone marrow of young adult mice
and the thymus of 14-d-old mouse embryos. These clones
represent the two earliest stages of T cell development
identified so far. We call them "marrow-type" and "thymus-
type" proT lymphocytes (reviewed in reference 13). Both types
of clones contain the TCR a, (3, y, and S genesin the germ-
line configuration. Thymus-type clones express mRNA from
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types of proT clones are Thy-1+ Sca-1-. Marrow-typeclones
grow in vitro in the presence of IL3 and IL4, and thymus-
type clones grow in IL2 or 114 (14-17). Both types ofclones
generate in vitro all major subsets of thymocytes, including
cells expressing TCR-a/ß-CD3, and cellsexpressing TCR-
y/S-CD3 receptor complexes on the cell membrane, if they
are cultured in the presence of thymic epithelial cells (18) .
We have developedapanel of ratmAbs against theseclones
in order to be able to identify these cells in vivo, to isolate
them, and to study their functional properties. ThreemAbs
(Joro30-8,Joro 37-5, andJoro 75) that were specific forunique
cell surface determinants of early T cell progenitors were
studied in detail and are the subject of the present report.
Materials and Methods
Animals.
￿
BALB/c, C57BL/6, and CBA/J normal female mice
(3-12 wk old) were from IFFA Credo (Saint-Germain, France).
BALB/c and C57BL/6 nu/nu mice (6-8 wk old) were from Bom-
holgard (Ry, Denmark). (NIH Swiss II nu/nu x CBA/N)F,
(xid/nu) female (6-8 wk old) mice, C.B. 17 Scid, and AKR Scid
(6-12 wk old) mice are bred and housed in sterile isolators in the
animal barrier facility of our institute. Scid mice without detect-
able serum Ig were used. C57BL/6 pregnant mice were from our
breeding facility. The dayofdetection of vaginal plug was consid-
ered day 0 of gestation.
CellPreparation.
￿
Cell suspensions were prepared free oferythro-
cytes from thymus, spleen, lymph nodes, bone marrow, and fetal
liver, as described(14, 19, 20). Cells were washed andresuspended
in appropriate buffer or culture medium (IMDM + 5% FCS +
2-ME [5 x 10-5 M], L-glutamine [2 mM], gentamycin [50 lAg/ml])
at the desired concentrations.
Cell Lines. Growth factor-dependent lines included bone
marrow proT lymphocyte clones (C4-77, C4-86, C4-95) (14); fetal
thymocyteclones (FTH5, FTFI, FTA2, FTG12, FTH12, FTD11)
(16, 17); bone marrow pro-B lymphocyte clones (CB/Bm7, BC/
Bmll, LyD9, LyH7) (19, 20); CD8- CD4- TCR-ci/ß-CD3'
LD1 Tcell line (21); myeloidprogenitor bone marrowclone Mye-5
(established with IL3 from bone marrow ofCBA/jmice)(Palacios,
R., unpublished results); IL3-dependent mast cell line (3213c1) (22);
11,2-dependent cytolytic T cell lines (CTLL, CFLI) (23, 24); and
Th cell line HT -2 (25). Tumorcell lines included thymic lymphomas
BW5147, EIL4; fetal liverpre-B cell lymphoma CgC (providedby
S. Carson, Basel Institute forImmunology, Basel); marrow pre-B
cell lymphomas (18.81, 40E1, 70Z/3); B cell lymphomas (BCL1,
WEHI-279, WEH1231); macrophage cell line (P388D1); mastocy-
toma (P815), myelomonocytic leukemia (WEHI-3), fibroblast lines
(L, 3T3).
Development ofJoro Hybridomas.
￿
Two Lewis rats were injected
each with 2 x 10' C4-77 proT cells (emulsified in CFA) in the
right hind foot pad. 3 d later, 2 x 107 C4-77 cells were injected
(without adjuvant)in thesame foot pad.4dafter thesecond injec-
tion, 2 x 10' C4-77 cells (without adjuvant) were injected again
in the same region. On the next day, the regional lymph nodes
from oneoftherats were obtained, cell suspensions were prepared,
and fused with the Ag8.653 myeloma cells as described (26). Su-
pernatants from wellsclearlycontaining growinghybridoma cells
were tested by flow fluorocytometry (FM)' analysis for reactivity
' Abbreviation used in this paper: FM, flow fluorocytometry.
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with the C4-77 proT lymphocyte clone. Supernatants that scored
positive on thesecells were subsequently screened on apro-Blym-
phocyteclone(CB/Bm7), apre-Bcell lymphoma (18.81),amacro-
phage line (P388D1), total thymocytes from adultmice, and 15-d
fetal liver mononuclear cells from CB57BL/6 embryos. Aliquots
ofalltheseJoro hybridomas were frozen. Threehybridomas called
Joro 30-8,Joro 37-5, andJoro 75 were selected for further study.
They were recloned twice by limiting dilution (0.5 cells/well) in
culture medium supplemented with IL-6. The class of rat Ig pro-
duced by the hybridomas was determined by ELISA with acom-
merciallyavailable kit (Amersham Corp., Arlington Heights, IL).
Joro 30-8-, Joro 37-5-, andJoro 75-purified mAbs were conjugated
to biotin-N-hydroxysuccinimide, as described before (27).
OuterAntibodies.
￿
Biotin-or FITC-conjugated antibodies were used
against: B-220 (hybridoma 14.8), IgM'j (hybridoma RS3.1), CD3
(hybridoma 145-C11), Thy-1.2 (hybridoma 30H12), CD8 (hy-
bridoma 5367.2), CD4 (hybridoma GK1.5). FITC-LyT2 and PE-
L3T4 were purchased from Becton Dickinson & Co. (Mountain
View, CA). The following antibodies were used in the form of
hybridomaculture supernatant: jlld,B-220 (hybridoma RA3-3A1),
M5/114 (IA, IE), PgP-1, (142/5), GM1.2 (granulocytes),andF4/80
(macrophages). Thereports describing thedevelopment and char-
acterization of these mAbs are listed elsewhere (14, 19, 20, 27).
Second-step reagents in FM analysis (see below) were: FITC-labeled
species-specific anti-rat IgG1, IgG2a, IgG2b, and IgM from the
BindingSite Ltd. (Birmingham, England). FITC-conjugated anti-
mouseA., anti-rat Ig were from Southern Biotechnology Associates
(Birmingham, ÁL). Biotin-labeled anti-rabbit IgGandFITC-labeled
streptavidin were from Amersham Corp.
Cytokines.
￿
rIIA0 (kindly provided by M. Brockhaus, Hoff-
mann-La Roche & Co. Ltd., Basel). Supernatants from X63Ag8
myeloma cellstransfected with cDNAscoding for11,2, 11,3, IL-4,
11,5, and l1r6 (28) and tested forbiologic activity in proliferative
assays, as described(20, 29), were used. 1 Uof activity wasconsid-
ered to the dilution of the supernatant given half of the maximal
responses. rII,,7 (30) was akind gift of Dr. S. Gillis (Immunex Corp.,
Seattle, WA).
Puriftcadon ofJoro' Bone Marrow Cells.
￿
Bone marrow cells from
3-wk-old CBA/J mice were depleted of B-220*, jlld*, la', and
GM1.2' cells by treatment with a mixture of cytotoxic mAbs
(RA3-3A1, j11d, M5/114, GM1.2) and complement as described
(14, 20, 27). This treatment killed 91-98% nucleatedbone marrow
cells, as assessed by trypan blue dye test. Purification ofJoro 30-
8', Joro 37-5', or Joro 75' marrow cells was carried out by cell
sorter (FRCS 440; Becton Dickinson & Co.) usingbiotin-labeled
Joro mAbs and FITC-streptavidin (27). After completion of the
cell sort, a fraction of the sorted cells were reanalyzed to assess
the degree of purification obtained. The results reported here are
from experiments performedwith marrow cell preparations in which
the highest degree ofpurification (99.0-99.5%) couldbe obtained
(see also Results and Discussion).
Assayfor Cell Proliferation.
￿
Cell sorter-purified Joro 30-8', Joro
37-5', and Joro 75' marrow cells were cultured at 5 x 103
cells/well in round-bottomed microplates (Nunc, Roskilde, Den-
mark)containing saturating concentrations of thevarious ILs (100
U/ml) (from rILlß to rIIr7) either alone or in several combina-
tions in a final volume of 200 A.1 of culture medium. Cultures in
triplicate were incubated at 37°C, and cell growth was assessed
both visually (with an inverted microscope) andby ['H]thymidine
uptake (1 uCi/well, sp act 185 MBq) (The RadiochemicalCentre,
Amersham Corp.) during thelast 8 h of a 3-d-culture period per-
formed at 37°C. The results are presented as cpm x 10-3 andrep-
resent the mean of triplicate wells per group.Assaysfor Functional Pbtential ofJoro* Cells.
￿
AKR scid mice ex-
posed to 350 rad (140 rad/min) of y rays (gamma cell 40; Atomic
Energy of Canada Ltd., Ontario) 20-24 h before were injected in-
travenously with cell sorter-purified Joro* marrow cells (2-2.5 x
UP cells/0.4 ml PBS/mouse) or PBS alone (controls). Before in-
jection into mice, the cell sorter-purified Joro* marrow cells were
incubated in culture medium supplemented with rIL3 + rIL4 at
37°C for 12 h to allow shedding of bound antibodies. Mice were
kept in cages with individual sterile filters in sterile isolators and
were fed with sterile food and water containing antibiotics.
In the experiments carried out to assess thymus recolonization
potential of Joro* cells, C57BL/6 mice were exposed to 600 rad
of.y rays (140 rad/min) to induce a wave of thymus recolonization.
The presence ofJoro 30-8*, Joro 37-5*, and Joro 75* cells in ei-
ther thymocyte cell suspensions was assessed by FM analysis daily
during 21 d using biotin-labeled Joro antibodies and FITC-
streptavidin, or in thymic tissue, sections were determined by im-
munoperoxidase staining (see below). Three mice were studied at
each time point.
FM Analysis.
￿
Immunofluorescence staining and FM analysis
was performed with a FACScan or a FACS I analyzer instrument
(Becton Dickinson & Co.) as described (18, 19, 27). Negative con-
trols were cells incubated with biotin-labeled anti-rabbit IgG fol-
lowed by FITC-streptavidin, and cells incubated with second-step
reagents only. Dead cells were excluded from analysis with pro-
pidium iodide. Fluorescence emitted by single viable cells was mea-
sured using logarithmic amplification. Two-color FM analysis was
carried out as detailed elsewhere (18), viable cells were identified
by using a combination of forward and side scatters. Thymocytes
from normal BALB/c or C57BL/6 mice were used as a positive
control and to set up electronical compensations for red and green
fluorescence. Data from 1-5 x 10' cells were analyzed with Con-
sort 30 software.
Immunoperoxidase Analysis. Frozen sections were cut from
thymuses of both normal C57BL/6 mice and mice exposed to
sublethal irradiation, placed on glass slides, fixed in acetone, and
dried at -30°C. Immunoperoxidase staining was carried out as
described (31) using biotinylated goat anti-rat Ig, the avidin-biotin
peroxidase complex, and 3.3'-diaminobenzidine (31). After this,
the slides were stained with Giemsa and processed for microscopic
examination (31).
Results and Discussion
Development ofJoro Hybridomas.
￿
A Lewis rat was im-
munized with C4-77 marrow proT cells in CFA in the footpad
and boosted 3 and 7 d later with these cells without adju-
vant. 1 d after the last injection, the regional cells were ob-
tained and fused with the HATresistant Ag8.653 myeloma.
Out of956 hybridomas tested, 184 produced antibodies that
bound to the marrow proT clone C4-77. The latter mAbs
were further screened by immunofluorescence staining and
FM for theirreactivity with a marrow pro-Blymphocyte done
(CB/Bm7), a pre-B cell lymphoma (18.81), a macrophage
tumor line (P388D1), total thymocytes from adult mice, and
mononuclear cells from 15-d-old fetal liver. Several poten-
tially interesting mAbs were found. In Table 1, they are
grouped according to their pattern of reactivities on the var-
ious cells tested. This report describes detailed studies with
three mAbs from group 1 called Joro 30-8 (IgM), Joro 37-5
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Table 1.
￿
Screening ofJoro Hybridomas
The grouping of the Joro hybridomas was made according to their
reactivity (assessed by FM) with ProT (C4.77), Pro-B (CB/Bm7),
Pre-B (18.81), MO (P388D1) lines, total thymocytes from adult
mice (A.T.) and mononuclear cells from 15-d fetal liver (F.L .). The
groups can further be subdivided according to the presence or ab-
sence of positive cells detected in adult thymus and fetal liver (not
shown).
(IgG2a), and Joro 75 (IgG2a). A preliminary account of this
work has been published in a recent review (13).
Reactivity ofJoro mAbs with Cell Lines.
￿
The specificity of
the Joro 30-8, Joro 37-5, andJoro 75 mAbs was determined
by FM usinga panel of cell linesrepresenting different hema-
topoietic lineages and distinct stages of T or B lymphocyte
development. The Joro 177 mAb that binds to all cells tested
was included in these studies as a positive control. The Joro
30-8, Joro 37-5, andJoro 75 mAbsbound to all marrow pro-T
clones (C4-77, C4-86, C4-95) and to all thymus-type proT
clones (FTH5, FTF1, FTG12, FTA2, FTH12, FTD11) tested.
However, they did not stain cell lines representing laterstages
of T cell development nor any other hematopoietic cell types.
The following cell lines were found to be negative: thymic
lymphomas BW5147 and ED4, a CD4-CD8- TCR-a/
a-CD3* T cell line (LD1), cytolytic T cell lines (CTLL,
CFL1), a Th cell line (HT2), pro-B lymphocyte clones (LyD9,
Bc/Bm11, LyH7, CB/Bm7), a fetal liverpre-B cell lymphoma
(CgC), marrow pre-B lymphomas (18.81, 40E1, 70Z/3), ma-
ture B lymphomas (BCL1, WEH1279, WEH1231), plasmacy-
tomas (HOPCI, SP2/0, X63Ag8), a macrophage cell line
(P388D1), a myelomonocytic cell line (WEHI-3), a mastocy-
toma (P815), IIJ3-dependent myeloid lines (32Dc1, Mye5),
and fibroblast cell lines (L, 3T3). Representative examples
are shown in Fig. 1. These analyses show that the Joro 30-8,
Joro 37-5, and Joro 75 mAbs bind to proT lymphocyte clones
but not to cell lines representing either later stages of T cell
development or other hematopoietic lineages.
Identification ofJoro* Cells in Tissues ofAdult Mice and Em-
bryos. Cell suspensions from various tissues of adult (6-12
wk old) normal mice as well as of immunodeficient mice car-
rying the nude, Scid, or both xid and nude (xid/nu) muta-
Group Pro-T Pro-B
Pattern
Pre-B
of
MO
reactivity
A .T . F .L.
No . of
hybridomas
1 + - - - ± ± 10
2 + - - + - ± 3
3 + + - - - ± 105
4 + + - - + ± 42
5 + + + - ± ± 2
6 + + - + ± ± 17
7 + + + + ± ± 5
8 - 772Marrow
PRO-T
C4-77
Thymus
PRO-T
FTH 5
Thymic
LYMPHOMA
BW5147
Mature
T
CFL 1
PRO-B
Ly D9
PRE-8
1&81
B
WEHI 279
Myeloid
PROGENITOR
Mye 5
tions was studied by FM analysis. Joro+ cells (<1%) were
not detected in lymph nodes, thymus, bone marrow, nor in
spleen of normal adult mice (BALB/c, C57BL/6, CBA/J).
Nude mice had in the bone marrow 1-4% cells, and in the
spleen, 1-3% cells that bound the three Joro mAbs, and
xid/Nu mice had 2-5% Joro cells in the marrow and 1-3%
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Figure 1 .
￿
Binding of the Joro mAbs to cell lines representing different hematopoietic lineages and distinct stages of T and B lymphocyte de-
velopment was studied by FM analysis using biotin-labeled Joro mAbs followed by FITC-streptavidin. The Joro 177 mAb served as positive
control.
in the spleen. CD17 Scid mice had no detectable (<1%) posi-
tive cells in the marrow and 2-4% spleen cells reactive with
the three Joro mAbs.
Next, we studied the liverand thymus from C57BL/6 em-
bryos. Table 2 summarizes the results of these experiments.
The three Joro mAbs bound to 1-3% nucleated fetal liverTable 2 .
￿
Ontogeny in Liver and Thymus from C57BL/6 Mice
of Cells Recognized by the Joro 30-8, Joro 37-5, andJoro 75 mAbs
Range of positive cells detected in three separate experiments . FM
analysis was carried out using biotin-conjugated Joro antibodies and
FITC-strepavidin .
cells from 14-d mouse embryos, with 45% at day 15 and
with -42% up to day 18 of gestation .
Joro 30-8 andJoro 75 mAbs bound to ;42%, and Joro 37-5
mAbbound to 73-85% thymocytes from day 14 mouse em-
bryos . Joro 37-5+ thymocytes decreased to <40% at day 16,
14-18% at day 17, and to <1% in thymuses from young
mice. Joro 30-8+ and Joro 75+ fetal thymocytes remained at
<2% from day 16 until birth .
The frequency and tissue distribution of cells that bind
Joro 30-8, Joro 37-5, and Joro 75 mAbs are consistent with
the results obtained with cell lines and strengthen the view
that these antibodies recognize early T cell precursors, but
not most of the adult thymocytes, mature T cells, B cell
precursors, mature B lymphocytes, or cells of the myeloid
lineage. In addition, these results point out that athymic nude
mice have increased numbers ofT cell precursors in the bone
marrow and spleen as compared with normal mice.
Purification ofJoro+ Bone Marrow Cells.
￿
To be able to
study the phenotype and functional properties ofJoro+ cells,
we isolated these cells from the bone marrow of 3-wk-old
CBA/J mice . First, we depleted bone marrow cell suspen-
sions ofirrelevant cells by treatment with a mixture of cyto-
toxic mAbs and complement, and then we isolated Joro+
cells using the FACS (see Materials and Methods for details) .
Fig. 2 shows with some examples that after antibody plus
complement killing of irrelevant cells (91-98% nucleated cells),
Joro+ cells (range 15-37%) were clearly detectable, whereas
no Joro+ cells (<I%) were found in marrow cell suspensions
before such treatment . After cell sorting, highly enriched popu-
lations ofJoro+ cells (range 87.8-99.5%) could be obtained.
The experiments described below were performed with
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Joro+ marrow cell preparations in which the highest degree
of purification (99-99.5%) could be obtained (Fig. 2) .
Phenotype ofJoro+ Marrow Cells. After an incubation
period at 37°C for 8-12 h, the cell sorter-purified Joro
30-8+, Joro 37-5+, and Joro 75+ cells were washed and pheno-
typed byFM analysis using a panel ofmAbs specific for cells
of the T, B, or myeloid lineages . The cell sorter-purifiedJoro
30-8+, Joro 37-5+, and Joro 75+ marrow cells express low
levels of Thy-1, but not CD8, CD4, andCD3 T cell lineage
markers . They are positive for PgP-1 and negative for IgM,
B-220, Ia, and F4/80 surface markers normally expressed by
cells of theB lymphocyte and the myeloid lineages . Interest-
ingly, N7-15% of the Joro 30-8+-purified marrow cells do
not bind the Joro 75 and Joro 37-5 mAbs, whereas all Joro
75+- and Joro 37-5+-purified marrow cells bind the Joro
30-8 mAb. Thus, there are at least two subsets ofJoro 30-8+
marrow cells, a small subset that lacks and a larger one that
expresses the molecules recognizedby theJoro 37-5 andJoro
75 mAbs .
Growth Requirements ofJoro+ Marrow Cells.
￿
The prolifer-
ative responses of cell sorter-purified Joro+ marrow cells
from CBA/J mice to saturating concentrations ofrILs alone
or in several combinations were assessed by [3H]thymidine
uptake during the last 8 h of a 3-d culture period . rIL3 and
rIIJ4 each promoted some proliferation ofJoro 30-8+, Joro
37-5+ , or Joro 75+ marrow cells, while rIIrl, rIIJ2, rIL5,
rIIr6, and rIIr7 did not . The combinations of rIL3 + rIIA
and rIL3 + rIIA + rllr6 gave the best responses (Fig. 3) .
Confirming these results, we have been able to establish con-
tinuously proliferating clones from Joro 30-8+ andJoro 75+
marrow cells with rIL3 + rIL4 and rIL3 + rIL4 + rl1r6
(Palacios, R., and J. Samaridis, manuscript in preparation) .
Functional Potential ofJoro+ Marrow Cells In Viva
￿
The
potential of cell sorter-purified Joro 30-8+, Joro 37-5+, and
Joro 75+ bone marrow cells to develop into mature T and/or
B lymphocytes from CBA/J mice was studied by injecting
them into sublethally irradiated (350 rad) T andB cell-deficient
AKR Scid mice. In this experimental system, the presence
of Thy-1.2+ and/or IgM+ lymphocytes detected by allotype-
specific mAbs in the recipient AKR Scid mice (Thy-1.1,
IgMd allotypes) mark T and B lymphocytes, respectively,
which originate from the donor Joro+ marrow cells from
CBA/J mice (Thy-1 .2, IgMJ allotypes) . Thymocyte cell
suspensions from Scid mice that had received Joro 30-8+-,
Joro 75+-, or Joro 37-5+-purified marrow cells contained
CD4+8- , CD4+8+, and CD4-8+ thymocytes, a proportion
of which were also CD3+ (Fig. 4, B-D) . Thymus from Scid
mice that received no marrow cells did not contain such thymo-
cyte populations (Fig. 4 A) . Mononuclear spleen cells from
AKR Scid mice that received cell sorter-purified Joro+
marrow cells or no cells (control) were obtained 8-12 wk
after transfer of the Joro+ marrow cells . The presence ofT
lymphocytes (Thy-1.2+, CD8+, CD4+, CD3+) and B lym-
phocyte lineage cells (B-220+, IgMJ+) was determined by FM
analysis. Table 3 summarizes the results obtained in the four
mice per group studied . Spleen cells from AKR Scid mice
injected with Joro 30-8+, Joro 37-5+, and Joro 75+ marrow
cells contained Thy-1.2+, CD4+, CD3+ and Thy-1.2+,
Organ
Day of
gestation
Percent positive cells
(FM analysis)
Joro 30-8 Joro 37-5 Joro 75
Liver 14 <2' <2' 2-3'
15 2-5 3-5 4-5
16 <2 2-3 2-3
17 <2 <2 <2
18 <1 <1 <1
Thymus 14 <2 73-85 <2
15 <2 67-82 <2
16 <2 25-39 <2
17 <1 14-18 <1
18 <1 <2 <1
Young adult <1 <1 <1Procedure :
￿
None
￿
mabs+C'treatment
￿
Cell sorter
JOR037-5+marrow cells
c
U
3 1 ' '
100
CD8+ , CD3* T lymphocytes . Spleen cells from mice that
received Joro 30-8+ marrow cells, but not from those mice
that received Joro 37-5+ or Joro 75+ marrow cells, also have
B-220+, IgMJ+ B lymphocytes. Control AKR Scid mice that
received no cells had no detectable Thy-1.2+, CD8+, CD4+,
CD3+ T cells nor IgMJ+, B-220' (<1-4.5%) B lymphocytes.
Thus, Joro 37-5+ and Joro 75+ marrow cells seem to be
functionally restricted to develop along the T lymphocyte
pathway, i .e ., they are pro-T lymphocytes. Further in vitro
experiments are in progress with Joro 75+ and Joro 37-5+
224
￿
Pro-T lymphocytes
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JORO30-8+marrow cells
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Fluorescence intensity
4
100 10 1 ]0 2 103 104
Figure 2 .
￿
The percentage of Joro 30-8', Joro 37-5', or Joro 75' cells in marrow cell preparations treated or left untreated with a mixture of
mAbs + C to eliminate irrelevant cells or after completion of the cell sort procedure was determined by FM analysis. Untreated and mAbs +
C'-treated marrow cells were stained with biotin-labeled Joro antibody followed by FITC-streptavidin . Cell sorter positively selected Joro 30-8*,
Joro 37-5*, or Joro 75* cells were reanalyzed after completion of the sort procedure. The data shown above were from experiments in which
the best degree of purification was obtained . These cell sorter-purified Joro * marrow cell preparations were used in the experiments summarized
in Table 3 and Fig. 3 .
marrow cells to subject the apparent restricted potential of
these cells to a more stringent test .
The Joro 30-8+ marrow cell population seems to comprise
both proT lymphocytes (all Joro 75*- and Joro 37-5+-puri-
fied marrow cells are Joro 30-8+) and lineage-uncommitted
lymphocyte precursors. The latter conclusion is based on the
following grounds : (a)Marrow cells representing the earliest
stage ofB cell development (before Ig gene rearrangement),
i.e., pro-B lymphocytes, are Joro 30-8 negative (Fig. 1) . (b)
The Joro 30-8+ marrow cell population comprises at leastFigure 3.
￿
Proliferative response to recombinant ILs of cell
sorter-purified Joro 30-8+, Joro 37-5+, or Joro 75+ marrow cells.
The results obtained with purified Joro 30-8* marrow cells are only
shown above, as similar results were obtained with purified Joro 75*
and Joro 37-5' marrow cells.
two subpopulations : Joro 30-8+, 75-, 37-5-, and Joro 30-
8+ ; and 37-5+ and 75+ . (c) We have established in culture
Joro 30-8+, 37-5-, and 75- bone marrow clones from 3-wk-
old CBA/J mice and find that they can generate both T and
B lymphocytes in vitro and in vivo (Palacios, R., and J .
Samaridis, manuscript in preparation) .
Thus, Joro 30-8+, 37-5+, 75+ marrow subset can give rise
to T lymphocytes, while Joro 30-8+ , 37-5-, 75- subset can
generate both T and B lymphocytes. We do not know yet
whether this latter subset can give rise also to myeloid cells .
Experiments with the Joro 30-8+, 37-5-, and 75- bone
marrow clones recently established in our laboratory are in
progress to directly address this issue .
Cell sorter-purified Joro! marrow cells from 3-wk-old CBA/J mice (see legend to Fig. 2) or PBS alone (control) were injected intravenously
into sublethally irradiated AKR Scid mice. 8-12 wk later, spleen cells from the different groups of mice were tested FM analysis for the
presence of cells expressing the surface markers indicated above. The numbers are the range of positive cells observed in the four mice per
group studied .
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Thymus Colonization by Joro+ Marrow Cells.
￿
To study
thymus colonization by Joro+ cells, we chose the following
experimental system . Normal young adult C57BL/6 mice
were exposed to a sublethal dose of irradiation (600 rad) to
induce a wave of thymus recolonization . As Joro+ cells are
not detectable by FM analysis in thymus ofyoung adult mice,
it was possible to follow the entry ofT cell progenitors into
the thymus by assessing the presence of Joro+ cells in the
thymus at different times post-irradiation . This was carried
out daily by FM analysis during a period of 21 d and by
studying three mice at each time point. Fig. 5 summarizes
the results of this experiment . Joro 30-8+, Joro 37-5+, and
Joro 75+ cells were detected in the thymuses' from day 2
post-irradiation . The frequency of cells positive for all three
Joro antibodies remained relatively constant up to day 6, de-
creased by day 7, and Joro+ cells could not be detected on
any of the following 13 d. The absolute number of Joro+
thymocytes increased from 1.08 x 1(14, 1.32 x 104, and
1.44 x 104 (Joro 30-8+, Joro 37-5+, and Joro 75+ cells,
respectively) at day 2, to 1.25 x 105 , 1.72 x 105, and 1.67 x
105Joro+ cells at day 6 post-irradiation . There was a good
correlation among the Joro 30-8+, Joro 37-5+, and Joro 75+
cells entering the thymus at any time point during the 5-d
period of colonization (Fig. 5), which is compatible with
the view that the colonizing cells bear all three Joro surface
markers. CD4+8- and CD4+8* thymocytes were observed
from day 5-6, and CD4-8+ thymocytes were detected from
day 9-10 post-irradiation (Fig. 5 B, and data not shown) .
These findings show that Joro+ cells enter the thymus 2 d
after irradiation, where they expand during the following
4 d and undergo further differentiation.
In another experiment following the same protocol as above,
the presence and the localization of Joro+ cells was deter-
mined by immunoperoxidase staining oftissue sections from
both normal thymus and thymuses obtained daily during the
first 8 d after sublethal irradiation of C57BL/6 mice. Very
few Joro 30-8+, Joro 37-5+, and Joro 75+ cells were found
in the thymus of normal C57BL/6 mice. Virtually all Joro+
cells were in the subcapsular area and in the outer cortex,
Table 3. Functional Potential of Cell Sorterpurifed Joro+ Marrow Cells In Vivo
Donor
marrow cells Thy-1 .2
Percent
CD8
positive in total
CD4
spleen cells (FM
CD3
analysis)
Igm B-220
None <1 <1-2 <1 <1 <1 <1-4.5
Joro 30-8 + 10.4-18.8 4-7.5 5.3-8.7 9.1-13.9 5-13.7 5.6-14.3
Joro 37-5' 14-19.7 4.5-8.9 4.7-12.1 12.2-16.8 <1 <1-3
Joro 75+ 9.1-20.5 5.6-9.4 3.2-9.3 9.0-18.0 <1 <1-4Figure 4.
￿
Two-color FM analysis of thymus from scid mice that had received Joro 30-8' marrow cells (B), Joro 37-5' marrow cells (C), Joro
75+ marrow cells (D), or PBS only (A) 8 wk before analysis.
but no Joro+ cells were found in the medulla (data not
shown) .
The analysis of tissue sections from thymus at 2 d post-
irradiation showed the presence of significant numbers ofJoro
30-8+, Joro 37-5+, and Joro 75+ cells. These Joro+ cells were
mainly in the subcapsular area and in the outer cortex but
not in the medulla, and they all exhibited a lymphoblastoid
morphology. Between days 4 and 6 post-irradiation, the
Joro+ cells tended to localize in the mid and deep cortex .
Thymuses obtained at day 8 post-irradiation contained fewer
Joro+ cells, which, like in the normal thymus, were in the
subcapsular region and outer cortex. For the sake ofbrevity,
Fig. 6 illustrates the results with some examples obtained with
the Joro 37-5 antibody only.
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Thus, the immunohistochemical analysis confirms and com-
plements the information obtained by FM analysis in a sepa-
rate experiment . Taken together, the results from these ex-
periments indicate first that there are normally very few Joro
30-8+, Joro 37-5+, and Joro 75+ lymphoid cells in the
thymus ofyoung C57BL/6 mice, and that they are preferen-
tially in the subcapsular area and outer cortex, but not in
the medulla . These Joro+ cells most probably represent re-
cent T cell progenitor migrants from the bone marrow.
Second, in the experimental system used here, the Joro+ cells
seem to colonize the thymus of sublethally irradiated mice
by entering via blood vessels through the subcapsular and
outer cortex regions, where they proliferate and subsequently
migrate to inner areas of the cortex . Most Joro+ cells mustFigure 5.
￿
The presence ofJoro 30-8 ', Joro 37-5', and Joro 75' cells in the thymocyte cell suspensions of C57BL/6 mice irradiated with 600
rad (140 rad/min) of .y rays was assessed by FM analysis daily during 21 d using biotin-labeled Joro antibodies with FITC-streptavidin . Negative
controls were cells stained with biotin-conjugated anti-rabbit IgG followed by FITC-streptavidin . The presence of CD4- 8', CD4'8', and
CD4'8- thymocytes was assessed by two-color FM analysis. The data in A show the percentage (mean t SD) of Joro' cells (", Joro 30-8' ;
O, 37-5'; p, Joro 75') detected in the three mice studied at each time point . B illustrates these results with some examples in the form of
fluorescence histograms or contour plots .
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￿
The presence and localization of Joro* cells in thymuses at various days post-irradiation of C57HL/6 mice was studied by immuno-
histochemistry . The results obtained with the Joro 37-5 mAb are only shown above for the sake of brevity and clarity. The same phenomena
was found with the Joro 30-8 and Joro 37-5 mAbs .
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no Joro+ cells are found in the medulla at any time, and since
fewer Joro+ cells were found at day 7-8 post-irradiation.
While our results are of relevance to the process of thymus
repopulation in the adult mice, it remains to be determined
whether this process follows a similar pattern in the mouse
embryo.
Concluding Remarks.
￿
The Joro mAbs described here ap-
pear to recognize cell surface determinants that are unique
for early lymphocyte precursors, although we cannot exclude
the possibility that they are also expressed by nonhemopoietic
cells. Our results suggest that in bone marrow ofyoung mice,
cells expressingJoro 30-8 are very earlyhematopoietic precursor
cells that are either committed to the lymphocyte lineage or
that are even less differentiated pluripotent cells. Commit-
ment to T cell differentiation seems to be associated with
additional expression of Joro 37-5 and Joro 75.
It should be stressed that the experiments reported here
were only designed to study hematopoietic cells that bind
to the Joro 30-8, Joro 37-5, andJoro 75 mAbs; hence, they
do not address the issue of whether the Joro antibodies de-
tect all precursor cells for T lymphocytes. Experiments to
define it are currently underway.
Recently it was shown that a Thy-1+ Sca-1+ population
of marrow cells highly enriched for pluripotent stem cells
give rise to thymocytes and peripheral T lymphocytes after
intravenous transfer, and that after their direct transfer into
the thymus of sublethally irradiated mice, a third of these
Thy-1+ Sca-1+ marrow cells grew in this organ (11). The in-
terpretation favored by the authors is that pluripotent stem
cells as such migrate to the thymus, and that commitment
to develop along the T cell pathway only takes place once
the stem cell has entered this organ (11). Our findings do
not necessarily argue against this scenario, but the present
results, as well as our previous studies (14, 32), and those
ofother groups (33-35), do provide strong evidence for the
existence of progenitorcells committed to the T cell lineage
before migration to the thymus.
It is possible that both proT lymphocytes and pluripotent
stem cells as such may colonize the thymus and generate T
lymphocytes. However, because the thymus-repopulating ac-
tivity of the Thy-1+ Sca-1+ marrow cell subset was assessed
14-28 d after their transfer, the possibility that Thy-1+ Sca-
1+ stem cells (assuming that the isolated population com-
prises only pluripotent stem cells) first generated proT lym-
phocytes, which in turn migrated to the thymus, was not
formally excluded (11). Actually, we have preliminary evi-
dence that stem cells generate in vitro Joro+ cells U.C.
Gutierrez and R. Palacios, unpublished observations). Also,
the results in the study of Sprangrude et al. (11), showing
that a third of a population of Thy-1+ Sca-1+ marrow cells
(clearly highly enriched for pluripotent stem cells) grew in
the thymus ofsublethally irradiatedmice aftertheirintrathymic
transfer (11), only documents that the thymic environment
of irradiated mice can support proliferation of some Thy-1+
Sca-1+ marrow cells. It does not address the issue of whether
or not pluripotent stem cells as such normally migrate to
the thymus via physiological routes (i.e., via blood). Several
types of T lineage cells (e.g., proT [131, CD4- 8- TCR/
CD3- thymocytes [361, CD4-8- TCR-a/0-CD3+ T cell
lines (21), CD4+8+ thymocytes [371) with or without the
capacity to repopulate the thymus via physiological routes
(after intravenous transfer) grow in the thymus after in-
trathymic injection. Thus, we think that direct evidence is
still needed to accept that pluripotent stem cells as such nor-
mally migrate and colonize the thymus. This may be feasible
to address when antibodies specific for pluripotent stem cells
become available, and performing kinetic studies such as those
used here to study the thymus repopulating potential of the
Joro+ cells.
The Joro 30-8, Joro 37-5, andJoro 75 mAbs together with
recently developed in vitro systems for T cell differentiation
(18) should facilitate the study of cellular and molecular events
of prethymic and early intrathymic phases of T lymphocyte
development. The specificity and development stage-restricted
expression of the molecules recognized by these mAbs raise
the possibility that they might function in early interactions
of proT lymphocytes with a set of bone marrow stromal
cells and thymic stromal components, perhaps as adhesion
molecules or ligands involved in homing to the thymus. We
shall now attempt to isolate cDNAs encoding the molecules
recognized by the Joro mAbs as a complementary approach
to determine their function.
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